Oncology & Cancer

Sorafenib modestly increases progression-free survival

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), ...

Oncology & Cancer

Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Oncology & Cancer

Nexavar approval expanded for common thyroid cancer

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Oncology & Cancer

Drug combination therapy causes cancer cells to 'eat themselves'

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain ...

page 2 from 4